Agents that increase GLP-1R signaling also appear to reduce the likelihood of developing diabetic retinopathy, AMD, cognitive dysfunction, motor dysfunction, stroke-induced neurodegenerative impairments, and neuropathy, supporting a potential neuroprotective effect of semaglutide in glaucoma. The gene discussed is GLP1R; the disease is diabetic retinopathy.